$GOVX
GeoVax Labs, Inc.

2023 Q2 Form 10-Q Financial Statement

#000143774923012551 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $81.53K
YoY Change -100.0% -26.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.459M $1.451M $1.179M
YoY Change 55.99% 23.1% 10.19%
% of Gross Profit
Research & Development $4.720M $2.819M $1.331M
YoY Change 261.06% 111.88% 120.73%
% of Gross Profit
Depreciation & Amortization $17.32K $17.32K $12.27K
YoY Change 41.16% 41.16% 171.62%
% of Gross Profit
Operating Expenses $6.179M $4.271M $2.510M
YoY Change 175.53% 70.17% 49.87%
Operating Profit -$6.179M -$4.271M -$2.428M
YoY Change 175.53% 75.89% 55.24%
Interest Expense $251.0K $232.7K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $251.2K $527.00
YoY Change 31737.9% -59.4%
Pretax Income -$5.928M -$4.038M -$2.428M
YoY Change 164.44% 66.34% 55.61%
Income Tax
% Of Pretax Income
Net Earnings -$5.928M -$4.038M -$2.428M
YoY Change 164.43% 66.34% 55.33%
Net Earnings / Revenue -2977.6%
Basic Earnings Per Share -$0.22 -$0.15 -$0.34
Diluted Earnings Per Share -$0.22 -$0.15 -$341.4K
COMMON SHARES
Basic Shares Outstanding 26.44M 26.33M 7.109M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.79M $23.85M $16.26M
YoY Change -42.44% 46.7% -21.99%
Cash & Equivalents $17.79M $23.85M $16.26M
Short-Term Investments
Other Short-Term Assets $2.038M $2.139M $279.7K
YoY Change 79.46% 664.87% 133.04%
Inventory
Prepaid Expenses
Receivables $99.53K
Other Receivables $0.00
Total Short-Term Assets $19.83M $25.99M $16.64M
YoY Change -38.11% 56.21% -20.63%
LONG-TERM ASSETS
Property, Plant & Equipment $224.1K $217.6K $206.9K
YoY Change 4.33% 5.19% 44.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.198M $1.198M $11.01K
YoY Change 21.29% 10779.09% 10.1%
Total Long-Term Assets $1.422M $1.415M $217.9K
YoY Change 18.26% 549.66% 41.26%
TOTAL ASSETS
Total Short-Term Assets $19.83M $25.99M $16.64M
Total Long-Term Assets $1.422M $1.415M $217.9K
Total Assets $21.25M $27.40M $16.85M
YoY Change -36.07% 62.59% -20.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $871.1K $1.288M $426.1K
YoY Change 267.08% 202.27% 83.28%
Accrued Expenses $3.214M $3.251M $3.075M
YoY Change 2.68% 5.73% 8296.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.086M $4.539M $3.501M
YoY Change 21.31% 29.65% 674.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $2.000M
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $2.000M
YoY Change -100.0% -100.0% 19900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.086M $4.539M $3.501M
Total Long-Term Liabilities $0.00 $0.00 $2.000M
Total Liabilities $4.086M $4.539M $5.501M
YoY Change -23.89% -17.49% 1085.31%
SHAREHOLDERS EQUITY
Retained Earnings -$88.36M -$82.43M -$66.80M
YoY Change 27.98% 23.4% 41.03%
Common Stock $105.5M $105.3M $78.16M
YoY Change 8.88% 34.73% 15.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.16M $22.87M $11.35M
YoY Change
Total Liabilities & Shareholders Equity $21.25M $27.40M $16.85M
YoY Change -36.07% 62.59% -20.18%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$5.928M -$4.038M -$2.428M
YoY Change 164.43% 66.34% 55.33%
Depreciation, Depletion And Amortization $17.32K $17.32K $12.27K
YoY Change 41.16% 41.16% 171.62%
Cash From Operating Activities -$6.037M -$3.763M -$4.333M
YoY Change 57.48% -13.16% 167.31%
INVESTING ACTIVITIES
Capital Expenditures $23.81K $0.00 $62.19K
YoY Change -217.93% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$23.81K $0.00 -$62.19K
YoY Change 17.93% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00 $9.229M
YoY Change -100.0% -100.0% -26.64%
NET CHANGE
Cash From Operating Activities -6.037M -$3.763M -$4.333M
Cash From Investing Activities -23.81K $0.00 -$62.19K
Cash From Financing Activities 0.000 $0.00 $9.229M
Net Change In Cash -6.061M -$3.763M $4.834M
YoY Change -141.39% -177.84% -55.89%
FREE CASH FLOW
Cash From Operating Activities -$6.037M -$3.763M -$4.333M
Capital Expenditures $23.81K $0.00 $62.19K
Free Cash Flow -$6.061M -$3.763M -$4.395M
YoY Change 58.94% -14.39% 171.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000832489
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2819189 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1330544 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1451425 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1179024 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4270614 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2509568 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4270614 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2428042 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
232698 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
527 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4037916 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2427515 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26338576
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7109473
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
26600034 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
75000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
228039 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4037916 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
22865157 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9229248 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190191 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2427515 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11353652 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4037916 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2427515 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17319 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12269 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
246039 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
205151 usd
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-0 usd
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
50520 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
755973 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-976498 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-208839 usd
CY2023Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
275044 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3762872 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
62186 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62186 usd
CY2023Q1 govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 usd
CY2022Q1 govx Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
9229248 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
24 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9229272 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3762872 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4833846 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27612732 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11423870 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23849860 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16257716 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
623824 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
606505 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
217593 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Nature of Business </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to herein as “GeoVax” or the “Company”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is focused on developing immunotherapies and vaccines against cancers and infectious diseases using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy for advanced head and neck cancer. Additional preclinical research and development programs include preventive vaccines against Mpox (monkeypox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa Fever) Zika virus, and malaria, as well as immunotherapies for solid tumors.</p>
CY2023Q1 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1962913 usd
CY2022Q4 govx Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1171077 usd
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
72013 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
107876 usd
CY2023Q1 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
13045 usd
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
91000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2138971 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1325998 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
841417 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
841417 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
234912 usd
CY2023Q1 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
1106778 usd
CY2022Q4 govx Prepaid Clinical Trial Expenses Noncurrent
PrepaidClinicalTrialExpensesNoncurrent
2083276 usd
CY2023Q1 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
80000 usd
CY2022Q4 govx Prepaid Technology License Fees
PrepaidTechnologyLicenseFees
80000 usd
CY2023Q1 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
11010 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1197788 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2174286 usd
CY2023Q1 govx Accrued License Fees Current
AccruedLicenseFeesCurrent
2000000 usd
CY2022Q4 govx Accrued License Fees Current
AccruedLicenseFeesCurrent
2000000 usd
CY2023Q1 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
127553 usd
CY2022Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
550810 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
1123507 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
449402 usd
CY2023Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3251060 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3000212 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
108696
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
13384115
CY2023Q1 govx Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
2.77
CY2023Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P4Y3M18D
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1221367 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2023Q1 govx Prepaid Expense Value Of Stock Issued For Services During Period
PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod
81000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15442915
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6846415

Files In Submission

Name View Source Status
govx-20230331_lab.xml Edgar Link unprocessable
0001437749-23-012551-index-headers.html Edgar Link pending
0001437749-23-012551-index.html Edgar Link pending
0001437749-23-012551.txt Edgar Link pending
0001437749-23-012551-xbrl.zip Edgar Link pending
ex_510145.htm Edgar Link pending
ex_510146.htm Edgar Link pending
ex_510147.htm Edgar Link pending
ex_510148.htm Edgar Link pending
ex_510149.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
govx-20230331.xsd Edgar Link pending
govx20230331_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
govx-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
govx-20230331_pre.xml Edgar Link unprocessable
govx-20230331_def.xml Edgar Link unprocessable
govx20230331_10q_htm.xml Edgar Link completed